TY  - GEN
AU  - Morgensztern, Daniel
AU  - Dols, Manuel Cobo
AU  - Ponce Aix, Santiago
AU  - Postmus, Pieter E.
AU  - Bennouna, Jaafar
AU  - Fischer, Jürgen R.
AU  - Juan-Vidal, Oscar
AU  - Stewart, David J.
AU  - Ardizzoni, Andrea
AU  - Bhore, Rafia
AU  - Wolfsteiner, Marianne
AU  - Reck, Martin
AU  - Talbot, Denis
AU  - Govindan, Ramaswamy
AU  - Ong, Teng Jin
PY  - 2021
DO  - 10.3389/fonc.2020.569715
UR  - http://hdl.handle.net/20.500.12105/18251
AB  - Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by...
LA  - eng
PB  - Frontiers Media
KW  - Advanced stage non-small cell lung cancer
KW  - Durvalumab
KW  - Immune checkpoint blocker plus chemotherapy
KW  - nab-paclitaxel
KW  - Second-line therapy
KW  - Carcinoma de pulmón de células no pequeñas
KW  - Puntos de control inmunológico
KW  - Quimioterapia
KW  - Humans
KW  - Female
KW  - Middle Aged
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Lung Neoplasms
KW  - Asthenia
KW  - Diarrhea
KW  - Mutation
KW  - Receptor Protein-Tyrosine Kinases
TI  - nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
TY  - research article
ER  -